Clinical Case Analysis: Dementia Diagnosis and Treatment for TM

QUESTION

TM is a 79-year-old man who was diagnosed with dementia 6 years previously. He lives with his 72-year-old wife. He was a chain smoker for 45 years. She describes a gradual deterioration in his condition such that in recent months she has found it increasingly difficult to manage him. He has become increasingly hostile and aggressive, though he has not actually assaulted her. He has begun to complain about seeing people wandering around the house, and that frightens him. On two occasions he has left the house and been found wandering along the road. She has noticed that his condition fluctuates – sometimes he is very aggressive and confused, while at other times he is more calm and lucid. Summarize the clinical case. What is the DSM 5-TR diagnosis based on the information provided in the case? Which pharmacological treatment would you prescribe according to the clinical guidelines? Include the rationale for this treatment. Which non-pharmacological treatment would you prescribe according to the clinical guidelines? Include the rationale for this treatment excluding a psychotherapeutic modality. Include an assessment of the treatment’s appropriateness, cost, effectiveness, safety, and potential for patient adherence to the chosen medication. Use a local pharmacy to research

ANSWER

Clinical Case Analysis: Dementia Diagnosis and Treatment for TM

Introduction

This clinical case presents TM, a 79-year-old man diagnosed with dementia six years ago. He lives with his 72-year-old wife, who has noticed a gradual deterioration in his condition. TM has a history of smoking for 45 years and is exhibiting symptoms such as aggression, visual hallucinations, and wandering. This essay aims to summarize the clinical case, provide a DSM-5-TR diagnosis, recommend pharmacological and non-pharmacological treatments, and assess their appropriateness, cost, effectiveness, safety, and potential for patient adherence.

Clinical Summary

TM’s clinical presentation includes several key symptoms indicative of dementia. He has shown a gradual cognitive decline over six years, with recent episodes of aggression, visual hallucinations, and wandering behavior. These symptoms suggest a complex manifestation of dementia, and further evaluation is required for a comprehensive diagnosis and treatment plan.

DSM-5-TR Diagnosis

Based on the information provided, TM’s clinical presentation aligns with the criteria for a diagnosis of Major Neurocognitive Disorder, previously known as dementia, according to DSM-5-TR. This diagnosis is supported by the presence of significant cognitive impairment, including memory deficits and impaired judgment, which interfere with his daily functioning. The emergence of behavioral and psychological symptoms, such as aggression and visual hallucinations, is also consistent with the diagnostic criteria.

Pharmacological Treatment

Pharmacological treatment for dementia typically involves cholinesterase inhibitors and/or memantine, depending on the specific subtype of dementia. Given TM’s presentation, a cholinesterase inhibitor such as donepezil (Aricept) may be considered. Donepezil is known to improve cognitive function and may help manage behavioral symptoms associated with dementia.

Rationale for Donepezil

Appropriateness: Donepezil is appropriate for TM’s diagnosis of Major Neurocognitive Disorder as it targets cognitive symptoms and may provide some relief from behavioral symptoms.
Cost: The cost of donepezil varies, but generic versions are available, which can be cost-effective.
Effectiveness: Research has shown that donepezil can improve cognitive function and quality of life in dementia patients.
Safety: Donepezil is generally well-tolerated, with side effects such as nausea and diarrhea being the most common. Monitoring TM for adverse effects is crucial.
Patient Adherence: Daily dosing with donepezil is relatively straightforward, which may enhance patient adherence.

Non-Pharmacological Treatment

Non-pharmacological interventions are essential in managing dementia. Given TM’s fluctuating condition and behavioral symptoms, a structured daily routine, environmental modifications, and caregiver support are crucial.

Rationale for Non-Pharmacological Treatment

Appropriateness: Non-pharmacological interventions are essential in managing dementia and can complement pharmacological treatment.
Cost: The cost varies but is generally lower than medication expenses.
Effectiveness: These interventions can improve the quality of life, reduce caregiver burden, and enhance patient safety.
Safety: Non-pharmacological approaches have minimal safety concerns when implemented correctly.
Patient Adherence: The success of non-pharmacological interventions depends on caregiver involvement and commitment to providing consistent support.

Conclusion

TM’s clinical case highlights the challenges of managing dementia, particularly in the presence of behavioral symptoms. A DSM-5-TR diagnosis of Major Neurocognitive Disorder is appropriate based on his clinical presentation. The pharmacological treatment of choice is donepezil, while non-pharmacological interventions, such as a structured daily routine and caregiver support, should be an integral part of the treatment plan. These approaches, when combined, can enhance TM’s quality of life, minimize caregiver burden, and promote patient safety. Close monitoring, both for medication side effects and the effectiveness of non-pharmacological strategies, is essential for providing the best care for TM and his wife.